Anavar (Female, 6 weeks)

Tmax oral-tablet mean verified; 9.5 h stays a conservative label-era assumption, not derived fromMCT 6.7 h.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

9.5 hours

Absorption half-life assumed

0.314692 hours

Reference amount for the relative scale

1 mg

• The faster rate is inferred to match the 1.6 h source-scoped peak time; absorption half-life 0.31469202358666837 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Exactmean dose/per-person dose-to-table mapping is absent; a cohort mean Cmax cannot be confidently assigned to 10 mg.
• A possible approximate reference is 8.45 mg (=0.1 mg/kg ×median 84.5 kg), but this is not a measuredmean dose and should require an explicitly accepted additional assumption.
• The 6.7 h mean belongs tobuccal MCT; tablets described as similar without a numericaltable half.
• Use relative output rather than silently choose a reference dose; fixed-dose FDA table remains a specific follow-up.

• Linakis 2020 oxandrolone oral/buccal MCT Table 4

  6 fasted men; oral 67.6 ng/mL, Tmax 1.6 h, 7.5–10 mg doses.62.5% is buccal MCT relative tooral; 6.7 h reported forMCT.

• FDA ANDA 076897 original approval package

  A fixed-dose tablet bioequivalence lead exists but was not successfully retrieved for table verification.

anavar-relative-timing-2026-10 · version 1